79 related articles for article (PubMed ID: 1889734)
1. [Does an increase in endogenous estradiol in treatment with low-dose ovulation inhibitors signify increased risk?].
Kuhl H
Geburtshilfe Frauenheilkd; 1991 Jun; 51(6):492. PubMed ID: 1889734
[No Abstract] [Full Text] [Related]
2. [Oral contraceptives: 30 vs 20 micrograms of ethinyl estradiol (EE)].
Urdinola J
Adv Contracept; 1994 Jul; 10 Suppl 1():41-9. PubMed ID: 7839871
[No Abstract] [Full Text] [Related]
3. [Clinical study of low-dose oral contraceptives (with low-doses of ethinyl estradiol), widely used in practice].
Nalbanski B; Tsekova K; Ivanov S
Akush Ginekol (Sofiia); 2001; 41 Suppl 4():20-3. PubMed ID: 11519317
[No Abstract] [Full Text] [Related]
4. [Modern extremely low dose oral contraception with lindynette 20].
Radinski G
Akush Ginekol (Sofiia); 2008; 47 Suppl 2():40-2. PubMed ID: 19504706
[No Abstract] [Full Text] [Related]
5. [Results of the "light pill" action].
Gerstner GJ; Kunze M
Gynakol Rundsch; 1989; 29 Suppl 2():469-71. PubMed ID: 2613077
[No Abstract] [Full Text] [Related]
6. [Ovulation inhibitors: the significance of estrogen dose].
Kuhl H
Geburtshilfe Frauenheilkd; 1990 Dec; 50(12):910-22. PubMed ID: 2086334
[TBL] [Abstract][Full Text] [Related]
7. [Low dose p-pills, Gynatrol and Mikrogyn].
Falck Larsen J
Ugeskr Laeger; 1976 Sep; 138(40):2446-7. PubMed ID: 969002
[No Abstract] [Full Text] [Related]
8. Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities.
Jendryczko A; Tomala J; Janosz P
Zentralbl Gynakol; 1993; 115(11):469-72. PubMed ID: 8296490
[TBL] [Abstract][Full Text] [Related]
9. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives.
Norris LA; Bonnar J
Thromb Haemost; 1994 Dec; 72(6):926-30. PubMed ID: 7740465
[TBL] [Abstract][Full Text] [Related]
10. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
Misz M; Beck P
Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
12. Change to Tri-Regol from other oral contraceptives.
Garamvölgyi G
Ther Hung; 1991; 39(3):122-4. PubMed ID: 1818425
[TBL] [Abstract][Full Text] [Related]
13. [Low dose oral contraceptives: 30 microg are still used?].
De Leo V; Caruso S; Scolaro V; Cianci A
Minerva Ginecol; 2009 Oct; 61(5):453-8. PubMed ID: 19749677
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
Johnson JV; Lowell J; Badger GJ; Rosing J; Tchaikovski S; Cushman M
Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963
[TBL] [Abstract][Full Text] [Related]
15. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
16. [Hormonal contraception and focal nodular hyperplasia].
Wedig MP; Altmann C
Zentralbl Gynakol; 1991; 113(24):1399-402. PubMed ID: 1667053
[TBL] [Abstract][Full Text] [Related]
17. [Comparative clinical investigation of oral contraceptives with different doses (author's transl)].
Mall-Haefeli M; Zodrow IW; Uettwiller A
Geburtshilfe Frauenheilkd; 1979 Jul; 39(7):553-7. PubMed ID: 467946
[TBL] [Abstract][Full Text] [Related]
18. [Modification of serum lipids and glucose tolerance by sequential Ovosiston and Minisiston].
Vesper VB; Feustel S
Zentralbl Gynakol; 1988; 110(4):241-5. PubMed ID: 2453102
[TBL] [Abstract][Full Text] [Related]
19. [Response to the letter by Prof. Kuhl: "Does a rise in endogenous estradiol during treatment with low-dose ovulation inhibitor signify increased risk"?].
Mall M; Werner-Zodrof I; Huber P
Geburtshilfe Frauenheilkd; 1991 Dec; 51(12):1014. PubMed ID: 1794681
[TBL] [Abstract][Full Text] [Related]
20. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
Cremer P; Vekemans M
Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
